JP Morgan Chase’s IGC Pharma IGC Stock Holding History

JP Morgan Chase’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4,917	Closed	-$1.38K	–	7620
2023 Q4	$1.38K	Buy	+4,917	New	+$1.52K	﹤0.01%	6786
2019 Q4	–	Sell	-200	Closed	–	–	5742
2019 Q3	$0	Buy	+200	New	+$241	﹤0.01%	5838

Other funds holding IGC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dearborn Partners Chicago, Illinois $1.85B AUM 6.59% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

JP Morgan Chase's IGC Position: Q1 2024 in Review

JP Morgan Chase sold out of IGC Pharma (IGC) in Q1 2024, closing a stake of 4,917 shares — an estimated $1.38K sold.

JP Morgan Chase first reported a position in IGC in Q3 2019 and held it in 2 quarters. The position peaked at $1.38K in Q4 2023. 25 funds tracked by Wall St. Rank hold IGC as of Q1 2024.

JP Morgan Chase reported no remaining IGC Pharma position as of Q1 2024 after selling out during the quarter.
JP Morgan Chase sold 4,917 IGC Pharma shares in Q1 2024, an estimated $1.38K.
JP Morgan Chase first reported a position in IGC Pharma in Q3 2019 and held it in 2 quarters.
JP Morgan Chase's IGC Pharma position peaked at $1.38K in Q4 2023.
25 funds tracked by Wall St. Rank held IGC Pharma as of Q1 2024.

Based on JP Morgan Chase's 13F filing for Q1 2024, filed 10 May 2024.